Shares of Celgene Corp. (NASDAQ:CELG) were up 4.1% on Wednesday . The stock traded as high as $104.94 and last traded at $104.32, with a volume of 4,226,863 shares trading hands. The stock had previously closed at $100.25.

Several analysts recently weighed in on CELG shares. SunTrust Banks Inc. reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Celgene Corp. in a research note on Wednesday, March 16th. Cowen and Company reissued an “outperform” rating and set a $150.00 price target on shares of Celgene Corp. in a research note on Wednesday, March 16th. Leerink Swann reissued a “market perform” rating on shares of Celgene Corp. in a research note on Sunday, April 10th. BMO Capital Markets began coverage on Celgene Corp. in a research note on Tuesday, April 5th. They set an “outperform” rating and a $129.00 price target on the stock. Finally, William Blair reissued an “outperform” rating on shares of Celgene Corp. in a research note on Wednesday, May 25th. Five equities research analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the stock. Celgene Corp. presently has an average rating of “Buy” and an average target price of $140.70.

The company has a market cap of $81.02 billion and a P/E ratio of 50.88. The stock’s 50 day moving average price is $102.00 and its 200-day moving average price is $104.07.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.29 by $0.03. During the same period last year, the business earned $1.07 EPS. The company had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.59 billion. The firm’s quarterly revenue was up 20.7% on a year-over-year basis. Equities research analysts anticipate that Celgene Corp. will post $5.67 earnings per share for the current year.

In other news, insider Robert J. Hugin sold 75,000 shares of the firm’s stock in a transaction on Monday, June 20th. The stock was sold at an average price of $100.16, for a total value of $7,512,000.00. Following the transaction, the insider now directly owns 1,122,201 shares in the company, valued at approximately $112,399,652.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Other institutional investors recently added to or reduced their stakes in the company. Swiss National Bank increased its position in Celgene Corp. by 1.5% in the fourth quarter. Swiss National Bank now owns 1,435,996 shares of the biopharmaceutical company’s stock valued at $171,975,000 after buying an additional 20,700 shares during the period. Honeywell International Inc. increased its position in Celgene Corp. by 68.9% in the fourth quarter. Honeywell International Inc. now owns 355,600 shares of the biopharmaceutical company’s stock valued at $42,587,000 after buying an additional 145,100 shares during the period. South Dakota Investment Council bought a new position in Celgene Corp. during the fourth quarter valued at $2,246,000. Gofen & Glossberg LLC IL increased its position in Celgene Corp. by 2.4% in the fourth quarter. Gofen & Glossberg LLC IL now owns 445,072 shares of the biopharmaceutical company’s stock valued at $49,786,000 after buying an additional 10,615 shares during the period. Finally, Alta Capital Management LLC increased its position in Celgene Corp. by 4.6% in the fourth quarter. Alta Capital Management LLC now owns 208,040 shares of the biopharmaceutical company’s stock valued at $24,914,000 after buying an additional 9,056 shares during the period.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.